Cargando…

Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes

Although phosphodiesterase type 5 inhibitors are widely used and well-studied drugs, the potential benefits of their application in the treatment of various diseases and new drug delivery systems, including liposome forms, are still being discussed. In this regard, the role of the lipid matrix of ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zakharova, Anastasiia A., Efimova, Svetlana S., Ostroumova, Olga S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622654/ https://www.ncbi.nlm.nih.gov/pubmed/34832122 http://dx.doi.org/10.3390/membranes11110893

Ejemplares similares

Fengycin induces ion channels in lipid bilayers mimicking target fungal cell membranes
por: Zakharova, Anastasiia A., et al.
Publicado: (2019)

Lipid Microenvironment Modulates the Pore-Forming Ability of Polymyxin B
por: Zakharova, Anastasiia A., et al.
Publicado: (2022)

Alkaloids Modulate the Functioning of Ion Channels Produced by Antimicrobial Agents via an Influence on the Lipid Host
por: Efimova, Svetlana S., et al.
Publicado: (2020)

1,3-Thiazine, 1,2,3,4-Dithiadiazole, and Thiohydrazide Derivatives Affect Lipid Bilayer Properties and Ion-Permeable Pores Induced by Antifungals
por: Zakharova, Anastasiia A., et al.
Publicado: (2020)

Is the Membrane Lipid Matrix a Key Target for Action of Pharmacologically Active Plant Saponins?
por: Efimova, Svetlana S., et al.
Publicado: (2021)

Chromone-Containing Allylmorpholines Influence Ion Channels in Lipid Membranes via Dipole Potential and Packing Stress
por: Efimova, Svetlana S., et al.
Publicado: (2022)

Modulation of the Dipole Potential of Model Lipid Membranes with Phytochemicals: Molecular Mechanisms, Structure–Activity Relationships, and Implications in Reconstituted Ion Channels
por: Efimova, Svetlana S., et al.
Publicado: (2023)

Blocking ion channels induced by antifungal lipopeptide syringomycin E with amide-linked local anesthetics
por: Zakharova, Anastasiia A., et al.
Publicado: (2018)

Dipole Modifiers Regulate Lipid Lateral Heterogeneity in Model Membranes
por: Efimova, S. S., et al.
Publicado: (2017)

Probing Amphotericin B Single Channel Activity by Membrane Dipole Modifiers
por: Ostroumova, Olga S., et al.
Publicado: (2012)

The Mechanisms of Action of Triindolylmethane Derivatives on Lipid Membranes
por: Efimova, S. S., et al.
Publicado: (2019)

A new look at Hsp70 activity in phosphatidylserine-enriched membranes: chaperone-induced quasi-interdigitated lipid phase
por: Tagaeva, Ruslana, et al.
Publicado: (2023)

Modifiers of the Dipole Potential of Lipid Bilayers
por: Efimova, S. S., et al.
Publicado: (2015)

The Degree of Hydroxylation of Phenolic Rings Determines the Ability of Flavonoids and Stilbenes to Inhibit Calcium-Mediated Membrane Fusion
por: Zlodeeva, Polina D., et al.
Publicado: (2023)

3-Amino-Substituted Analogues of Fusidic Acid as Membrane-Active Antibacterial Compounds
por: Salimova, Elena V., et al.
Publicado: (2023)

Triggering the Amphotericin B Pore-Forming Activity by Phytochemicals
por: Efimova, Svetlana S., et al.
Publicado: (2023)

Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs
por: Shekunov, Egor V., et al.
Publicado: (2023)

Investigation of Channel-Forming Activity of Polyene Macrolide Antibiotics in Planar Lipid Bilayers in the Presence of Dipole Modifiers
por: Efimova, S. S., et al.
Publicado: (2014)

The Interaction of Dipole Modifiers with Polyene-Sterol Complexes
por: Ostroumova, Olga S., et al.
Publicado: (2012)

Discovery of the Potentiator of the Pore-Forming Ability of Lantibiotic Nisin: Perspectives for Anticancer Therapy
por: Chernyshova, Dayana N., et al.
Publicado: (2022)

The Mechanisms of Lipid Vesicle Fusion Inhibition by Extracts of Chaga and Buckthorn Leaves
por: Efimova, S. S., et al.
Publicado: (2022)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Semisynthetic Amides of Amphotericin B and Nystatin A(1): A Comparative Study of In Vitro Activity/Toxicity Ratio in Relation to Selectivity to Ergosterol Membranes
por: Tevyashova, Anna, et al.
Publicado: (2023)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Plant Alkaloids Inhibit Membrane Fusion Mediated by Calcium and Fragments of MERS-CoV and SARS-CoV/SARS-CoV-2 Fusion Peptides
por: Shekunov, Egor V., et al.
Publicado: (2021)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Pore-forming activity of new conjugate antibiotics based on amphotericin B
por: Efimova, Svetlana S., et al.
Publicado: (2017)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Novel Semisynthetic Derivatives of Bile Acids as Effective Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
por: Salomatina, Oksana V., et al.
Publicado: (2018)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_blbm6e7e43tkk30brrt6e2524r